Nasdaq grants Epix conditional listing
The Nasdaq listing qualifications panel has granted biopharmaceutical company Epix Pharmaceuticals' request for continued listing on the Nasdaq Global Market, with the condition that on or before May 11, the company file a current report on Form 8-K with the Securities and Exchange Commission (SEC).
In the SEC filing, Nasdaq is requiring evidence of the company's compliance with Nasdaq Marketplace Rule, which requires the company to maintain a shareholders' equity of at least $10 million, or a minimum market value of listed securities of $50 million.
The Lexington, Mass.-based Epix said it is taking steps to comply with the terms of the panel decision; however, there can be no assurance that the company will be able to do so.
In the SEC filing, Nasdaq is requiring evidence of the company's compliance with Nasdaq Marketplace Rule, which requires the company to maintain a shareholders' equity of at least $10 million, or a minimum market value of listed securities of $50 million.
The Lexington, Mass.-based Epix said it is taking steps to comply with the terms of the panel decision; however, there can be no assurance that the company will be able to do so.